1,721,735 research outputs found
Convair B-36B
No full text1/2 right side view of a Convair B-36B military plane on the ground.https://corescholar.libraries.wright.edu/special_ms223_photographs/2247/thumbnail.jp
098. John 12:36b-43
No full textChapel Sermon by Jason Kohm from John 12:36b-43 on Thursday, February 29, 2024
Curtiss-Wright P-36B
No full text1/4 left side view a of Curtiss-Wright P-36B, a military plane, on the ground.https://corescholar.libraries.wright.edu/special_ms344_photographs/1242/thumbnail.jp
Memorial Gymnasium, University of Idaho. [61-36b]
No full text1925 photograph of Memorial Gymnasium. View of Cadets on walkway. [PG1_61-36b
Crew of B-36B plane No.69
No full textPhotograph of the crew of the B-36B airplane No. 69 standing on the ground near the nose. The men are (L-R): P. Gerbaz, C.J. Driskell, R.E. Fisher, G.W. Hofeller, L.C. Brandvig, and W. J. Martin. Their luggage sits on the ground next to them
Recommended from our members
Transiting Exoplanet Monitoring Project (TEMP). V. Transit Follow Up for HAT-P-9b, HAT-P-32b, and HAT-P-36b
No full text© 2019. The American Astronomical Society. All rights reserved. During the past five years, 6, 7, and 26 transit observations were carried out for the HAT-P-9b, HAT-P-32b, and HAT-P-36b systems, respectively, through the Transiting Exoplanet Monitoring Project network. Combined with the published photometric data and radial-velocity measurements, our new photometry allows us to revisit the system parameters and search for additional close-in planetary companions in these hot Jupiter systems. We measure an updated R P /R ∗ = 0.1260 ±0.0011 for HAT-P-36 system in the R band, which is 4.5σ larger than the published i-band radius ratio of 0.1186 ±0.0012. We also perform a transit timing variation (TTV) analysis for each system. Because no significant TTVs were found, we place an upper mass limit on an additional planet for each system
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells
No full textHM781-36B is an orally administered pan-human epidermal growth factor receptor (HER) inhibitor. To explore the role of pan-HER inhibitor in breast cancer, we investigated the antitumor effect and mechanisms of HM781-36B in breast cancer cell lines. Six breast cancer cell lines (BT474, MDA-MB-453, SK-BR-3, T47D, MCF-7, and MDA-MB-231) were tested. The growth inhibitory effect was assessed using the tetrazolium bromide [3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl-tetrazolium bromide] assay. The cell cycle at various concentrations of HM781-36B was analyzed by flow cytometry, and analysis of downstream molecules was performed by western blot analysis. Interaction of HM781-36B with cytotoxic chemotherapeutic agents was analyzed by combination index using CalcuSyn. The HER2-amplified cells (SK-BR-3, BT474, and MDA-MB-453) were sensitive to HM781-36B (IC50 = 0.001 mu mol/l, 0.0012 mu mol/l, and 0.0095 mu mol/l, respectively). HM781-36B induced G1 arrest and resulted in apoptosis. It reduced the level of p-HER2, p-AKT, p-ERK, and p-STAT3. HM781-36B combined with 5-fluorouracil, cisplatin, paclitaxel, or gemcitabine showed a synergistic inhibitory effect on the HER2-amplified and on some of the HER2-nonamplified breast cancer cells. HM781-36B could be a promising treatment for HER2-amplified breast cancer as a single agent or in combination with cytotoxic agents and can be a candidate for treatment of HER2-nonamplified breast cancer in combination with cytotoxic agents. Anti-Cancer Drugs 23: 288-297 (C) 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.N
- …
